Inclusion Criteria:  Patients with unresectable stage III NSCLC who completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy without evidence of disease progression Patients who have participated in the Durvalumab EAP in Brazil and have received at least one dose of Durvalumab in the EAP..